Theralase Technologies Inc. V.TLT

long haul vs short term

[DJDawg]

If TLT were only a bladder cancer company I would be nervous, mainly because having only one drug and one indication is a bit risky for a company.

However, the antiviral, vaccine and rutherrin (GBM, NSCLC) avenues are really exciting and promising.

I have not problem holding and waiting but I wish the company were more competent at raising funds as the ruvidar slowdowns and delays have impacted getting cash for moving rutherrin along.

[rollthedice10]

I agree totally. Roger has done an amazing job of attracting cash over the years but I think Theralase is entering a whole new world where we will need lot's and lot's of cash and other resources to get TLT into the big leagues where it belongs. The rewards I think will be enormous for anyone funding this or involved in a JV or other arrangement with TLT. Shareholders will share in the

[DJDawg]

Agreed. Medical advances come in waves. Immunotherapy and checkpoint inhibitors have been a big part of oncology but they are more like delaying agents whereas, done right, rutherrin has the potential to be curative in some cases. And via a mechanism that doesn't lead to chemo-resistance. Exciting times.